ck-0045
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 26, 2022 (NCT05712876)
Timeline
Indications
Mechanism of action
- Interleukin-22AGONIST
IL22 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06611930 | Phase 2 | Sep 16, 2024 | Cytoki Pharma, Profil GmbH |
| NCT05712876 | Phase 1 | Dec 26, 2022 | Cytoki Pharma, SGS Life Sciences |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cytoki Pharma | For profit | 2 | 2 | 2 | 2022 |
| Profil GmbH | For profit | 1 | 0 | 1 | 2024 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1